连续生命体征数据分析与静脉乳酸对创伤性休克患者救命干预预测的比较
本研究为对300例前瞻性入组创伤患者的预先计划二次分析,在直升机上采集静脉血用便携设备检测乳酸,同时收集连续生命体征,最终166例有完整数据。采用正则化梯度提升框架和10折交叉验证建模,并用SHAP分析。连续生命体征模型预测接受救命干预和ICU住院时长的表现优于单次生命体征测量;预测24小时内出院的能力与乳酸模型相当(连续生命体征模型AUROC 0.71,95%CI 0.68-0.75 vs 乳酸模型AUROC 0.65,95%CI 0.66-0.71);使用全部实验室数据的模型灵敏度最高(AUROC 0.77,95%CI 0.74-0.81)。作者认为,航空医疗环境中自主监测仪获取的连续生命体征可能有助于预测创伤成人对救命干预和重症监护的需求,早期无创生理数据可能有助于开发识别潜在不稳定创伤患者的早期预警系统。
要点
- 连续生命体征模型预测接受救命干预和ICU住院时长的表现优于单次(初始)生命体征测量。
- 预测24小时内出院时,连续生命体征模型AUROC 0.71(95%CI 0.68-0.75),乳酸模型AUROC 0.65(95%CI 0.66-0.71),两者表现相当。
- 使用全部实验室数据的模型灵敏度最高,AUROC 0.77(95%CI 0.74-0.81)。
- 作者认为,航空医疗环境中自主监测仪获取的连续生命体征可能有助于预测创伤成人的救命干预和重症监护需求。
- 作者认为,院前早期采集和使用无创生理数据可能有助于开发识别潜在不稳定创伤患者的用户友好型早期预警系统。
适用人群与场景
- 前瞻性入组的300例创伤成人,最终166例有完整生命体征和实验室数据可供分析。
- 患者在直升机上于院前环境采集静脉血,并被转运至马里兰州主要的成人创伤资源中心。
研究设计与关键结果
- 研究类型:对300例前瞻性入组患者的预先计划二次分析;最终166例有完整连续生命体征和实验室数据。
- 干预与对照:在直升机上采集静脉血用便携实验室设备分析乳酸,同时收集连续生命体征;采用正则化梯度提升框架和10折交叉验证建模,并用SHAP分析。
- 连续生命体征模型预测接受救命干预和ICU住院时长的表现优于单次(初始)生命体征测量。
- 预测24小时内出院:连续生命体征模型AUROC 0.71(95%CI 0.68-0.75) vs 乳酸模型AUROC 0.65(95%CI 0.66-0.71),两者表现相当。
- 使用全部实验室数据的模型灵敏度最高,AUROC 0.77(95%CI 0.74-0.81)。
证据类型、等级与局限
- 证据类型:对前瞻性入组患者的预先计划二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,航空医疗环境中自主监测仪获取的连续生命体征可能有助于预测创伤成人的救命干预和重症监护需求。
- 作者认为,院前早期采集和使用无创生理数据可能有助于开发识别潜在不稳定创伤患者的用户友好型早期预警系统。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Introduction: The prehospital environment is fraught with operational constraints, making it difficult to assess the need for resources such as lifesaving interventions (LSI) for adults with traumatic injuries. While invasive methods such as lactate have been found to be highly predictive for estimating injury severity and resource requirements, noninvasive methods, to include continuous vital signs ( VS ), have the potential to provide prognostic information that can be quickly acquired, interpreted, and incorporated into decision making. In this work, we hypothesized that an analysis of continuous VS would have predictive capacity comparable to lactate and other laboratory tests for the prediction of injury severity, need for LSIs and intensive care unit admission. Methods: In this preplanned secondary analysis of 300 prospectively enrolled patients, venous blood samples were collected in the prehospital environment aboard a helicopter and analyzed with a portable lab device. Patients were transported to the primary adult resource center for trauma in the state of Maryland. Continuous VS were simultaneously collected. Descriptive statistics were used to describe the cohort and predictive models were constructed using a regularized gradient boosting framework with 10-fold cross-validation with additional analyses using Shapley additive explanations (SHAP). Results: Complete VS and laboratory data from 166 patients were available for analysis. The continuous VS models had better performance for prediction of receiving LSIs and intensive care unit length of stay compared to single (initial) VS measurements. The continuous VS models had comparable performance to models using only laboratory tests in predicting discharge within 24 h (continuous VS model: area under the receiver operating curve [AUROC] 0.71; 95% CI, 0.68-0.75 vs. lactate model: AUROC, 0.65; 95% CI, 0.68; 95% CI, 0.66-0.71). The model using all laboratory data yielded the highest sensitivity and sensitivity (AUROC, 0.77; 95% CI, 0.74-0.81). Discussion: The results from this study suggest that continuous VS obtained from autonomous monitors in an aeromedical environment may be helpful for predicting LSIs and the critical care requirements for traumatically injured adults. The collection and use of noninvasively obtained physiological data during the early stages of prehospital care may be useful for in developing user-friendly early warning systems for identifying potentially unstable trauma patients.
参考来源
- Yang S, Hu P, Teeter W, et al. COMPARISON OF CONTINUOUS VITAL SIGNS DATA ANALYSIS VERSUS VENOUS LACTATE FOR THE PREDICTION OF LIFESAVING INTERVENTIONS IN PATIENTS WITH TRAUMATIC SHOCK. Shock. 2024. PMID: 39447081. doi:10.1097/SHK.0000000000002474
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。